

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care - The Mark Foundation names 2026 Emerging Leader Award recipients
- Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers










